CompletedPhase 2NCT04573309

Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

Studying Wilson disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alexion Pharmaceuticals, Inc.
Principal Investigator
Eugene S. Swenson, MD, PhD
Alexion Pharmaceuticals, Inc.
Intervention
ALXN1840(drug)
Enrollment
9 enrolled
Eligibility
18 years · All sexes
Timeline
2020 – 2022

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04573309 on ClinicalTrials.gov

Other trials for Wilson disease

Additional recruiting or active studies for the same condition.

See all trials for Wilson disease →

← Back to all trials